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Abstract
Direct RNA Sequencing of E. coli initiator tRNA Using the MinION Sequencing
Platform
by
Vinay C. Poodari
Transfer RNAs (tRNAs) are small RNA molecules responsible for decoding the
genetic code into an amino acid sequence. tRNAs bring amino acids to the ribo-
some, playing an active role in translation. tRNAs are vital to living systems and
can impact human health, making them clinically relevant. This motivates the de-
velopment of high throughput methods to screen and sequence tRNAs. Nanopore
sequencing, specifically the commercialized MinION sequencing platform presents
an opportunity to directly sequence tRNAs. I have developed a framework for
direct RNA sequencing of both biological and synthetic canonical E. coli initiator
tRNA that will be expanded to other tRNAs. I discuss the methods developed
to sequence tRNAs on the MinION. This includes improving coverage on the ter-
minal ends of the tRNAs, in vitro production of tRNAs, and the detection of
modified nucleosides using the MinION platform. The work presented here is
intended to be a launching point for further sequencing of tRNAs and modifica-
tion discrimination on the MinION. This work culminates in presenting distinct
differences between the alignment profiles of biological E. coli fmet tRNA and
a canonical version due to the presence of modified nucleosides on the biological
tRNA. This has implications for both direct sequencing of tRNAs and the broader
goal of detecting modified nucleosides.
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Chapter 1
Introduction
tRNAs, are essential to the central dogma of biology and are one of the most
abundant nucleic acids in cells [13]. During translation, tRNAs form codon-
anticodon pairs with mRNA in the ribosomal complex. tRNAs also bring with
them the corresponding amino acids encoded by the mRNA strand to initiate or
extend the nascent polypeptide chain. While tRNAs are small in sequence length,
they are very complex. tRNAs have a strong secondary structure, cloverleaf in
shape, made up of 4 loop regions [12]. It is estimated that there are 595 tRNA
genes in the human genome and in simpler prokaryotes such as E. coli, 89 tRNA
genes, both more than the 64 possible codon-anticodon pairs in the translation
paradigm [23]. The narrow distribution of tRNA sizes and sequence conserva-
tion have lead researchers to believe that primordial tRNAs were the basis of
translation with the modern ribosome appearing later in evolution [12].
The complexity of tRNAs is not limited to their abundance or their role in
translation; tRNAs are also heavily modified. There are more than 70 different
known modifications on tRNA molecules [6]. These modifications are necessary
for accurate translation, maintaining tRNA structure and charging tRNA with
the proper amino acid [6]. Improper modification states can lead to a variety
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of disease phenotypes often in mitochondria [1]. In eukaryotes the majority of
tRNAs are nuclear encoded, however mitochondria also have a small set of tRNAs
(mt-tRNAs) encoded in their genomes. The number of mt-tRNAs varies among
species with humans having 22 mt-tRNAs, but others less relying on nuclear
encoded tRNAs [16]. In humans mutations in mt-tRNA genes can have impacts
on health and fitness. Many ailments such as cardiomyopathy, aural and visual
impairments, and cancers are due to sequence mutations in mt-tRNA[1]. The
vital role of tRNAs and their impacts on human health necessitates methods to
better screen and categorize tRNAs. These screening methods need to be scalable,
low cost, and require rudimentary lab skills for accessibility in various clinical
environments.
There are multiple methods for detecting and categorizing tRNAs, the most
commonly used are mass spectrometry, hybridization arrays, and next generation
sequencing, NGS [23]. These methods have shown promise, but suffer from scal-
ability or information loss. Mass spectrometry identifies tRNA by digesting the
tRNA into either fragments or nucleosides. The mass spectra is then used to sep-
arate species of tRNA from one another [23]. Mass spectrometry is very sensitive
however sequence determination of the tRNA by mass spectrometry is difficult.
Mass spectrometry is also not practical in all clinical settings. The machines re-
quire a large area of space and the technical skills needed to run experiments and
interpret data requires additional training. Other methods such as oligo arrays
rely on tRNA molecules to anneal to probes. Annealing can be inhibited by strong
secondary structure and modifications on the tRNA, both prevent binding to oligo
probes [7]. In addition arrays need to be very specific as the difference between
two tRNAs can be a single base and without the primary sequence it is impossible
to separate two similar tRNA [23]. Next Generation Sequencing techniques are
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the logical choice and many methods to sequence RNA have been developed. One
of the most popular methods is sequencing by synthesis i.e. Illumina. Sequencing
by synthesis requires generating cDNA copies of the tRNA and sequencing the
cDNA. Sequencing by synthesis has many problems as the reverse transcription
step can be stymied by the secondary structure of the tRNA and modifications
can halt the enzyme, leading to inefficient full length cDNA production [24]. Mul-
tiple methods to circumvent these problems have been developed. This includes
removing methylation modifications or using more robust reverse transcriptase
enzymes, such as TGIRT, to increase the yield of full length cDNA [23, 24]. The
problem with sequencing by synthesis is that the original tRNA is not sequenced.
Information regarding the modification states of nucleosides is not represented in
the cDNA. This information is lost. The modification information could differ-
entiate tRNAs, and more importantly directly recognizing modification presence
can be important in recognizing diseases.
I show that MinION sequencing is a viable method to sequence tRNAs directly.
Nanopore sequencing has been developed over the last decade for single molecule
sequencing of DNA. The system uses an applied voltage to thread nucleic acid
fragments through a single biological nanopore embedded in a lipid membrane.
As the nucleic acid translocates through the pore, there is a measurable change in
current creating blockade events [8]. An enzyme such as a helicase or polymerase
regulates the rate that nucleic acids move through the pore so measurements can
be made as each nucleotide enters the pore. The measured current can then be seg-
mented into discrete events or states and converted into a nucleotide sequence [8].
There is a variety of research focusing on the applications of nanopore sequenc-
ing including detection of nucleoside modifications which has shown significant
promise [8, 17, 19].
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The UCSC Nanopore group has translocated tRNA through a nanopore chan-
nel [18]. These experiments used a single α-hemolysin pore. These experiments
did not produce sequence level data as the α-hemolysin pore used reads 10-15 nu-
cleotides at a time, making discrimination of each nucleotide difficult and beyond
the scope of the work [3, 11]. Smith et al. showed the blockade events of E. coli
initiator (fmet) tRNA translocating through a nanopore are different than those
of lysine tRNA [18]. This work showed that tRNAs can be differentiated by the
current signal. While the single channel experiments did not provide sequencing
data, translocation and differentiation of tRNAs on a nanopore based system was
validated. Nanopore sequencing has been commercialized by Oxford Nanopore
Technologies (ONT). Their flagship device, the MinION, uses 2048 pores to di-
rectly sequence nucleic acids providing base level resolution. The MinION plat-
form was developed for long read DNA sequencing and can directly sequence RNA
molecules. The UCSC Nanopore group adapted the methods of tRNA capture
and translocation developed by Smith et al. to the MinION. This was done by pro-
ducing a set of splint adapters that ligate to the NCCA overhang on the 3′ end of
the tRNA. The splint adapters also ligate to the conventional sequencing adapters
developed by ONT. The Nanopore group sequenced synthetic bovine tRNA con-
structs on the MinION. These constructs were comprised of only canonical bases,
however the group was able to demonstrate that these constructs can translocate
through the MinION nanopore, and are basecalled into nucleotide sequences. The
initial goal was to produce a set of synthetic molecules and train a classifier to
classify bovine mt-tRNAs, based on sequence. There were unanticipated com-
plications with T7 transcribed tRNAs for nanopore sequencing. This resulted in
constraining the problem to sequencing biological and a synthetic canonical E.
coli initiator tRNA and determine if reported modifications could be detected on
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the MinION. To better sequence these two tRNA molecules, the set of adapters
originally used by the Nanopore group were modified resulting in better 3′ and 5′
coverage. I show that there is a significant difference between the biological and
synthetic tRNA alignments due to the presence of modified nucleosides which has
been confirmed with mass spectrometry testing.
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Chapter 2
Methods
The methods section details materials, oligos, and general protocols used. The
reference sequences for designing tRNA constructs are available on Modomics [2].
The bioinformatic tools used to produce and visualize alignments are also dis-
cussed.
Oligos:
In vitro transcription (IVT) template:
Template sequence:
TGGTAGTACGGGAAGGATATAAACCAACATTTTCGGGGTATGGGCCC
GATAGCTTAATTAGCTGACCTTACTAATAGTGAGTCGTATTAAATGAT
GATG
The DNA template used to produce the bovine initiator mt-tRNA was synthesized
by Integrated DNA Technologies (IDT), rehydrated in NF H2O to produce a 100
µM stock and kept at -20°C. This template is based on the reference sequence
available at Modomics [2]:
AGUAAGGUCAGCUAAUUAAGCUAUCGGGCCCAUACCCCGAAAAUGUU
GGUUUAUAUCCUUCCCGUACUACCA
T7 RNA polymerase will include an initial adenine in the transcript, the tRNA
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encoded in this template also starts with an adenine. In order to avoid consecutive
adenines at the start of the tRNA, the region encoding the tRNA in the template
was adjusted to start encoding from the second position of the tRNA onwards.
In vitro transcription promoter:
CATCATCATTTAATACGACTCACTATTA
T7 RNA polymerase requires the T7 promoter region to be double stranded. This
DNA oligo hybridizes to the template oligo to form the duplex promoter region.
It was also synthesized by IDT, and kept at -20°C after being rehydrated in NF
H2O to produce a 100 µM stock.
AS102 and M221:
The AS102 and M221 adapters were synthesized by IDT. They were gel purified
by colleagues during their early attempts at sequencing tRNAs and stored at -
80°C.
Modified AS102_18 and M221_6:
AS102 and M221 adapters were modified such that both adapters are DNA/RNA
hybrid oligos. They are 5′ phosphorylated and ordered from IDT. The adapters
were modified so that there are ribonucleotide regions flanking the tRNA on both
ends. AS102_18 consists of 18 ribonucleotides flanking the tRNA at the 5′ side
and M221_6 has 6 ribonucleotides adjacent to the 3′ overhang of the tRNA.
M221_6 was purified using HPLC purification by IDT. Oligos were rehydrated in
NF H2O to make a 100 µM stock. Adapter oligos were stored at -80°C.
E. coli biological fmet construct:
Biological E. coli fmet tRNA was recovered from storage. It was manufactured
by Subriden RNA, no longer in business, and was previously used for functional
tests. In older mass spectrometry data, data not shown, this tRNA showed the
presence of modifications. This tRNA was gel purified and then aliquoted. The
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biological tRNA was phosphorylated using PNK (NEB: M0201S) before being
used for ligation and libraries. The purified tRNA was kept at -80°C.
E. coli synthetic fmet construct:
This phosphorylated oligo was synthesized by Dharmacon. The following sequence
from Modomics was ordered [2]:
CGCGGGGUGGAGCAGCCUGGUAGCUCGUCGGGCUCAUAACCCGAAGG
UCGUCGGUUCAAAUCCGGCCCCCGCAACCA
It was rehydrated in NF H2O, aliquoted, and stored at -80°C.
Urea Gels:
TBE urea gels were made in 75 mL batches with 7.5 mL 10x TBE buffer, 15
mL 40% bis-acrylamide, 37.7 grams of urea, and filled up to 75 mL with Milli-
Q H2O. The solution was mixed using a magnetic stirrer until clear and then
488 µL 10% APS and 48.8 µL TEMED were added to polymerize the mixture.
While the solution was mixing, glass plates were washed with Milli-Q H2O and
EtOH. The plates were then dried. The gel mix was poured between two glass
plates and allowed to polymerize for 30-45 minutes. After polymerization the gel
was prerun for at least 20 minutes at 25 watts while the samples were prepared
in 2-9x sample volume of urea load (7M urea and 0.1x TBE) depending on the
maximum capacity of the wells. After adding urea load, samples would be mixed
by pipetting or flicking, then heated to 90°C for 5 minutes. In many gels NEB
2x RNA dye, B0363S, rather than urea load was used. The NEB 2x RNA dye
contains formamide which resolved smaller fragment bands better. When using
2x RNA dye NEB instructions were followed. The ladder used in all the PAGE
results shown is NEB low range ssRNA ladder (NEB: N0364S), unless otherwise
specified. After loading samples, gels were run for 50-60 minutes at 23 watts. If
the loading dyes, bromophenol blue and xylene cyanol, were running unevenly
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across the gel a metal plate was placed on top of the glass plates to improve heat
distribution. Gels were stained with 6x-8x SYBR gold stain in 50 mL 1X TBE
solution. Staining was done in the dark for 15 minutes, before gels were visualized.
In Vitro Transcription Reaction:
In order to produce the bovine fmet tRNA at a low cost, a commercial T7 IVT
kit was used. The kit used was the Hiscribe T7 Quick High Yield kit from NEB
(E2050s). The template DNA oligo and promoter oligo from IDT were hybridized
together, using a heat and slow anneal process. T7 requires the promoter region
be double stranded. 33 pmols of the template was mixed with 165 pmols of the
complementary promoter oligo and allowed to hybridize in TNE buffer. The total
volume was 7 µL. Hybridization was done by heating the mixture to 75°C for 15
seconds and slowly cooling to 25°C at 1.6°C/minute. After hybridization, NEB’s
standard RNA synthesis protocol for the kit was followed. 1 µL RNasin (Promega:
N2611) was added to prevent RNA degradation. The total reaction volume was
kept at 20 µL. IVT reactions ran overnight, 16 hours minimum, at 37°C. The next
morning 2 units DNAse I (NEB: M0303) and the supplied 10x reaction buffer was
added raising the reaction volume to 30 µL with the addition of NF H2O. DNAse
I treatment took 15 minutes at 37°C. The next step is to extract and precipitate
the tRNA produced.
Phenol/Chloroform Extraction:
The IVT reaction was prepared for a phenol/chloroform extraction by bringing up
the volume of the reaction to 200 µL with NF H2O. 20 µL of 3M sodium acetate
was added to the reaction, followed by a 200 µL 1:1 mixture of acidic phenol, pH
4.3, to chloroform. DNA LoBind tubes are recommended for all work. The sample
was vortexed and well mixed before being spun at 10,000 RCF for 5 minutes in a
microcentrifuge. This centrifuge was kept at 4°C. The organic layer was removed
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with gel loading tips, and 200 µL of chloroform was added. The sample was then
vortexed again and spun at the same parameters. The chloroform wash and spin
was repeated once more. After the last spin most of the organic layer was removed
and the sample was spun for the last time to separate out the organic and aqueous
layer. The aqueous layer was collected and placed in a new tube.
Ethanol (EtOH) Precipitation:
After the phenol/chloroform extraction, the volume of collected aqueous layer was
measured and 2.5x volume of 100% EtOH was added to the sample. The reac-
tion was then stored at -80°C until it could be purified, usually overnight. The
mixture was taken out the freezer and spun down for 30 minutes at maximum
RCF in a microtube centrifuge kept at 4°C. The supernatant would be removed
after confirming a pellet was visible and 500 µL of 80% EtOH was added to the
pellet. The tube was respun for 20 minutes and the supernatant removed. The
same ethanol wash and spin was repeated. After the second wash the supernatant
was removed and the pellet was air dried. The pellet was then rehydrated with
NF H2O and RNA concentration was measured with a NanoDrop 1000 using the
default ssRNA mode, aiming for A260/280 and A260/230 ratios of 2.0. If at any
times a pellet was not visible the tube would be respun. Free NTPs may still be
present after EtOH precipitation, affecting quantification. Bio-Rad P6 (7326221)
columns were used to remove any excess NTPs after EtOH precipitation. The
recommended protocol from Bio-Rad was followed. The P6 columns come pack-
aged in buffer, which was replaced with NF H2O following the additional steps
Bio-Rad recommends for buffer exchange. 40 µL of the precipitated IVT reaction
was loaded onto a P6 spin column and RNA concentration was measured on a
NanoDrop 1000.
Preparing IVT Product for Ligation with RppH:
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One major limit of IVT products is additional processing is needed for efficient
ligation to occur. IVT products may contain 3′ non-templated ends and have a
5′ triphosphate. Both result in inefficient ligation of the splint adapters. A loss
was taken on molecules with non-templated nucleotides as those are expected to
be the minority product. The 5′ end of the tRNA was made amenable for ligation
by using RNA 5′ Pyrophosphohydrolase (RppH) purchased from NEB, catalog
#M0356. The NEB decapping eukaryotic mRNA with RppH protocol was used
with some modifications. The amount of IVT produced tRNA substrate was in-
creased to 3 µg and the reaction was run for 6 hours with 25 units of enzyme.
This reaction was then purified using a phenol/chloroform extraction and ethanol
precipitation, similar to the methods above. 3M NaOAc was added twice, once
before the addition of phenol and before adding EtOH with the belief that it would
improve recovery. In addition 1 µL molecular biology grade glycogen at 20mg/ml
(ThermoFisher/Fermantas) was added to help precipitate the tRNA, after adding
EtOH. The extracted sample would be placed at -80°C and purified in 1 to 3
days. The EtOH precipitation used a similar protocol mentioned previously with
the wash steps using 150-200 µL of 80% EtOH.
Phosphorylation of E. coli fmet tRNA:
The biological tRNA was phosphorylated using T4 PNK (NEB: M0201S). 400
pmols of tRNA was mixed with 5 µL of T4 DNA Ligase 10x reaction buffer and
20 units of enzyme. NF H2O was added to bring the reaction volume to 50 µL.
The mix was heated to 37°C for 30 minutes. The tRNA is then purified using a
phenol/chloroform extraction. The method above was used, however 3M NaOAc
was added at the end. The amount of NaOAc added was 10% of the recovered
volume. 1 µL molecular biology grade glycogen, 20mg/ml, was added to help pre-
cipitate the tRNA, before placing the sample at -80°C. EtOH precipitation used
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two 200 µL washes of 80% and 100% EtOH. The sample was eluted in 11 µL of
NF H2O.
Library Preparation:
All libraries were run as similar to each other as possible, there are variances in
SPRI cleanup and elution volumes for the following runs, the two biological runs
on 11/14/18 and 10/17/18 used 4.4x SPRI wash as these libraries were made
before experimenting with the SPRI cleanup procedure. The 02/04/19 run used
the SQK-RNA002 kit, ONT phased out the older SQK-RNA001 kits, and had an
elution volume of 21 µL.
Splint Ligation:
All libraries were prepared using ONT's SQK-RNA001 or SQK-RNA002 proto-
col, except with the following changes. The RTA was replaced with either AS102
and M221 or AS102_18 and M221_6 adapters. The adapters are prepared by
hybridizing 100 picomol of each adapter in 10 µL volume containing NF H2O and
1X TNE, creating a 10 µM stock of hybridized adapter. Adapters were hybridized
by heating the reaction up to 75°C for 15 seconds and slowly cooling to 25 °C at
1.6°C/minute. This process takes approximately 31 minutes.
10 pmols of tRNA and NF H2O are mixed and heated to 90°C for 20 seconds to
denature the tRNA. This allows the adapters and tRNA to anneal. The tRNA is
then allowed to cool for several minutes on ice. The next step is to add the follow-
ing components: 8 pmols of hybridized adapter, 2 µL PEG 8K, 2 µL 10x T4RNL2
reaction buffer, 1 mM ATP, 6.25 mM DTT, and 6.25 mM MgCl2. 5 units T4 RNA
Ligase 2 (NEB M0239S) are added last, bringing the total volume of the reaction
to 20 µL. The ligation occurs at room temperature for 45 minutes. 1 µL of the
crude ligation reaction was often saved for PAGE to verify proper ligation. The
ligated material was purified using RNAClean XP SPRI beads (Beckman Coulter
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Life Sciences: A63987) either 4.4x or 1.8x the volume of the reaction. The beads
incubated with the ligation reaction for 20 minutes in a LoBind Eppendorf tube.
The tube was placed on a magnetic rack for 10 minutes to pellet the beads. The
supernatant was removed. The beads were washed with 150 µL of 80% EtOH
wash followed by a 150 µL 100% EtOH wash. The tube was switched between
alternate sides of the magnet 4 times to clean the beads, between each EtOH
wash. This action forces the beads to move through the wash. The final reaction
was eluted in 11.5 µL NF H2O, over a 20 minute period with occasional flicking.
RMX Ligation and Loading:
The RMX ligation requires the following components: 6 µL of the RMX adapter,
5 µL of the NEB 5x Quick Ligation Reaction buffer (NEB: B6058S), 11 µL
of the splint ligation, and 3 µL of 2,000,000 units/mL T4 DNA ligase (NEB:
M0202S/M0202M). RMX adapter is included in ONT's RNA sequencing kits. If
needed, NF H2O was added to increase the reaction volume to 25 µL. The reaction
was carried out at room temperature for 30 minutes. 1 µL of this reaction was
often saved for a gel, before starting the SPRI cleanup. The reaction was then
purified with 2.5x or 1.5x SPRI beads. ONT's wash protocol for the second liga-
tion was followed. The reaction was eluted in 12.5 µL elution buffer, using a 20
minute elution time. 1 µL of the reaction was used for NanoDrop quantification,
to confirm presence of RNA. ONT protocol was followed for final preparation of
the sample and the flow cell before loading. Sequencing runs were less than 24
hours of runtime due to events that lead to flow cell deterioration. Continuous
data was collected for the first 1-2 hours of sequencing. When nanopores in the
flow cell were clogged, the experiment was restarted; most sequencing runs would
be restarted 4 or 5 times.
Bioinformatics Work:
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All data was basecalled using Guppy version 2.1.3. Reads were aligned to a
tRNA reference sequence that included the ribonucleotide portions of the adapters.
BWA-MEM, version 0.7.17-r1188, with the following settings, “-W 13 -k 6 -x
ont2d” was used for all alignments [9]. The SAM files were filtered for primary
alignments using SAMtools version 1.6 and viewed using the Broad Institute's
Integrative Genomics Viewer (IGV) version 2.4.14 [10, 15]. Full length reads were
determined using SAMtools to filter reads that aligned to the terminal 3 bases
AS102/AS102_18 adapters at the 3′ side and within the subset of those reads
filtered down to reads that also aligned to the CCA tail of the tRNA. In addition
these regions were used to calculate coverage on either ends of the tRNA. These
regions were chosen based on two criteria, they are both close to the ends of the
tRNA and the coverage of the region is fairly high regardless of sample. See sup-
plements for IGV screen captures.
Liquid Chromatography/Mass Spectrometry Analysis for RNA Modi-
fications of E. coli fmet tRNA:
Mass spectrometry was performed using modified ribonucleoside standards and on
tRNA digested to ribonucleosides using three different enzymes. The method used
was derived from Crain [5]. The standards are 4-thiouridine, 2′-O-methylcytidine,
7-methylguanosine, and 5-methyluridine. 60 ng of each standard was mixed into
0.1% formic acid in NF H2O, to be run either individually or as a mix. This
was used to find retention times of the expected modifications. The E. coli fmet
tRNA is reported to have dihydrouridine, as well. A commercial standard was
unavailable making it difficult to unequivocally determine the presence of this
modification. Both the biological tRNA and canonical version which is used as a
negative control were digested. 4 µg of each tRNA was first digested with 1 unit of
nuclease P1 (Sigma Aldrich: N8630-1VL) in a 10 µL solution of 10 mM NH4OAc
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and NF H2O. This mix was incubated in a thermocycler at 45°C for 2 hours.
The tRNA is then digested with 0.004 units Phosphodiesterase 1 (Thermo Fisher
Scientific: AAJ20240EXR) in 50 mM NH4HCO3, and 2.5 mM MgCl2 with H2O
up to 20 µL. The reaction was heated to 37°C for 3 hours. The final digest used
Antarctic Phosphatase (NEB: M0289S). The enzyme was mixed with the supplied
buffer as this dilution is easier to pipette. The enzyme mix is then added to the
reaction such that final concentration of Antarctic Phosphatase buffer is 0.2x and
0.5 units of Antarctic Phosphatase are in the reaction. The reaction volume to-
taled 25 µL adding NF H2O as needed, and was incubated at 37°C for 1 hour. 50
µL of 0.1% formic acid solution in NF H2O was added to the digested sample. The
sample is then purified by loading the sample onto a Nanosep 3k column and then
spun for 10 minutes at 14,000 RCF. The flowthrough is collected and placed into
vials. LC-MS/MS was done at UC Santa Cruz, with the LTQ-Orbitrap Velos Pro
MS from ThermoFisher, in positive ion mode. The column used was the Synergi
4 µm Fusion-RP 80Å C18 column manufactured by Phenomenex. Two solvents
were used A, which is composed of 0.1% formic acid in NF H2O and B, which is
0.1% formic acid in acetonitrile. The software used to control the LC-MS/MS is
Thermo Fisher's Xcalibur software and was also used for data analysis.
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Chapter 3
Results and Discussion
IVT production of bovine fmet tRNA:
In vitro transcription with T7 RNA polymerase was done to produce bovine
mitochondrial initiator (bovine fmet) tRNA for libraries. NanoDrop measure-
ments of the IVT product estimated an abundance of tRNA was being produced,
however initial gel electrophoresis experiments conflicted with these estimates.
In order to confirm the production of bovine fmet tRNA different masses of the
IVT product were loaded onto a gel for visualization. These masses are based
on NanoDrop measurements and all values are expected to be visible on PAGE.
In Figure 3.1, lanes 2-5 contain IVT product loaded from 5 picomoles, (115 ng)
to 150 picomoles (3.4 µg) of tRNA. The IVT reaction was treated with DNAse
I. Any visible bands are indicative of partial or complete RNA product. Lane
1 contains the DNA template, 99 bases used in the IVT reaction. There is no
evidence of any residual DNA template in lanes 2-5. The IVT tRNA is 72 bases,
and in lanes 2, 3, and 4 there is a band present between 50 and 80 bases. Lane
2 contains 150 picomoles of tRNA in this lane. There are bands below 50 bases.
These faint bands suggest incomplete product is being produced. Lane 5 contains
16
5 picomoles of tRNA, however there are no visible bands. This is surprising as 5
picomoles of the tRNA is more than a 100 ng of material. This amount of mass
is expected to be visible on PAGE stained with SYBR Gold. Lane 4 contains 3
times the amount material as lane 5, however the band in lane 4 is faint. This
suggests that the NanoDrop is overestimating the concentration of the sample,
potentially due to free NTPs that are not removed during the phenol/chloroform
extraction and EtOH precipitation. To remove smaller fragments and NTPs, Bio-
Rad P6 columns were used to further purify the IVT reaction. The NanoDrop
measurements of the P6 purified tRNA were more consistent. This leads to the
conclusion that the IVT production process requires more stringent purification.
The current method is an extraction followed by EtOH precipitation and addi-
tional P6 column filtration. In order to avoid tandem purification methods, future
work will likely use gel purification methods as the band of interest can be excised
out. In addition a secondary method of quantification such as Qubit may provide
more accurate measurements.
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The following 8% PAGE, stained with SYBR gold, shows IVT produced
bovine tRNA loaded onto a gel at various quantities based on NanoDrop
quantification. This was diagnostic to determine if the NanoDrop was ac-
curate and visualize the production of any partial products.
The gel to the right is both labeled at
the top and bottom. All samples were in
buffer of 7M urea and 0.1x TBE.
L) NEB low range ssRNA ladder
1) Template oligo: DNA template for the
mitochondrial bovine initiator tRNA.
2) 150 pmols, 3.4 µg, of IVT produced
bovine fmet tRNA. There is evidence of
some partial product.
3) 50 pmols, 1.16 µg, of IVT produced
tRNA
4) 15 pmols, 347.5 ng, of IVT produced
tRNA
5) 5 pmols, 115.8 ng, of IVT produced
tRNA. There are no bands visible in this
lane.
L) NEB low range ssRNA ladder
Figure 3.1: IVT Production of Bovine fmet tRNA
Determining Efficacy of RppH:
After producing the IVT construct, the splint adapters and ONT RMX adapters
were ligated to the tRNA and sequencing runs were carried out. Sequencing runs
had low throughput. The number of basecalled reads was much lower than ex-
pected for the MinION. The initial hypothesis was that RppH was inefficient in
converting the 5′ triphosphate into a monophosphate for ligation. To test this
hypothesis tRNA treated with RppH and untreated tRNA were ligated with the
splint adapters. In addition, tRNA treated with RppH at 42°C, rather than the
NEB recommended 37°C was also ligated. Since tRNA has a strong secondary
18
structure, heating the reaction to a higher temperature may better allow RppH
access to the tRNA to cleave the 5′ triphosphate. As a positive control, E. coli
fmet tRNA was ligated with M221 and AS102 adapters. The biological E. coli
tRNA is expected to have the proper 5′ monophosphate end for ligation.
Figure 3.2 shows all ligation reactions. Lane 1 contains the IVT produced
tRNA, 72 bases, below the 80 base marker as expected. Lanes 2 and 3 are ligations
with tRNA treated by RppH at 37°C and 42°C. Visually it is apparent they are
very similar. Ligation of the adapters to the tRNA has 3 possible configurations.
The first is ligation of both ends to the tRNA getting a product of 126 bases
in length. The other two configurations are ligation to only the 3′ side of the
tRNA with M221, 102 bases, or ligation of the 5′ side of the tRNA with AS102,
96 bases. In both the 37°C and 42°C reaction lanes all 4 bands are visible. The
IVT produced tRNA, is a visible band below the 80 base marker. There are 3
bands between 80 and 150 bases, corresponding to each of the possible ligations.
The top band is the complete ligation product. When looking at the negative
control in lane 4 there is only one band above the 80 base marker. The negative
reaction was not treated with RppH therefore, only 3′ ligation is possible. In the
-RppH lane there is only single band which migrates down between 80 and 150
bases corresponding to the expected size of 102 bases. In lanes 2 and 3 there is
a size shift of the tRNA band compared to lane 1, this is likely due to the RppH
treatment. The tRNA band in -RppH migrates to same position as in lane 1.
Lanes 5 and 6 show ligation of the E. coli fmet tRNA. Lane 5 contains the
tRNA by itself and is 77 bases long. It runs very close to the 80 base marker
as expected. In lane 6 there are two distinct bands above the tRNA. One is the
complete ligation and the second is a partial ligation. Without another marker
it is difficult to tell whether it is a partial ligation due to just 5′ ligation or 3′
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ligation, however the complete product is formed. In addition to the major bands
corresponding to ligation products, there are also faint bands higher up which
may be material that has not denatured.
Figure 3.2 shows that RppH does cleave the 5′ triphosphate to make it amenable
for ligation. An important caveat is that ligation efficiency is relatively low, and
needs to be improved. RppH inefficiency is unlikely to be the cause of the clogs
faced in early experiments. The splint ligation is not efficient as there is still
unligated tRNA, even in the biological E. coli fmet tRNA. In the RppH negative
lane the 3′ ligation band is the dimmest. This suggests that M221 ligation may
help stabilize the AS102 adapter facilitating complete ligation. This is based on
the fact that 3′ ligation, 102 bases, in the 37°C and 42°C is faint in both lanes.
However, the dynamics appear to be more complicated as the 5′ ligation by itself
happens as often as the complete ligation as well. This gel also confirms that the
E. coli tRNA was able to ligate as efficiently as the IVT product; this was a piv-
otal moment leading to a switch between working with IVT constructed tRNAs
and sequencing this biological sample. The IVT preparation of tRNAs takes a
significant amount of time, to produce and purify. In addition a bulk scale RppH
reaction is needed to purify enough material before ligation can even occur. Mod-
omics reports the presence of modifications on the E. coli fmet tRNA; this lead to
shifting the focus of the work to sequencing biological tRNA and to understand
how modifications affect MinION basecalling [2]. For others who wish to use IVT
to generate material for sequencing, it is beneficial to do a bulk RppH reaction,
followed by a bulk splint ligation. Then use any method of choice to preferentially
select for completely ligated material such as gel purification.
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Figure 3.2: Verification of RppH Activity and Splint Ligation
This 8% PAGE, stained with SYBR gold, shows ligations of IVT product
after RppH treatment at various temperatures along with a negative control.
The RppH treated lanes show that the RppH is necessary to get complete
ligation of the splint adapter, 126 bases. Lanes 5 and 6 are E. coli fmet
tRNA followed by ligation. The E. coli tRNA is a positive control. All
samples are in NEB 2x RNA dye.
L) NEB low range ssRNA ladder
1) IVT bovine fmet tRNA, expected to
be 72 bases
2) Ligation using RppH treated IVT
tRNA. The RppH reaction was carried
out at 37°C. Two partial ligations with
each half of the adapter are believed to
have occurred, the bands are labeled 5′
96 and 3′ 102. The complete ligation is
believed to be the band labeled T 126.
3) Ligation using RppH treated IVT
tRNA. The RppH reaction was carried
out at 42°C. The bands are very similar
to lane 2.
4)The negative control lane; the IVT
tRNA was not treated with RppH.
There is evidence of partial ligation due
to M221 being able to ligate to the 3′
side of the tRNA.
L) NEB low range ssRNA ladder
5) Biological E. coli fmet tRNA, 77
bases.
6) Ligation of the E. coli fmet tRNA,
the complete ligation is expected to be
at the band labeled T 131.
Optimizing SPRI Cleanup:
After confirming the ligation of the E. coli fmet tRNA and activity of RppH,
Figure 3.2, I attempted to sequence E. coli fmet tRNA. These sequencing runs also
had low throughput, this lead to a new hypothesis that free adapter and unligated
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tRNA are unable to completely translocate through the nanopores. When these
analytes get stuck in the nanopore an electronic feedback system attempts to eject
them. When sequencing tRNAs, these small molecules fail to get ejected.
The SPRI cleanup is a key part of library preparation. The beads bind the
nucleic acid, separating the tRNA from the enzymes and the reaction buffer. The
original protocol developed by the Nanopore group required 4.4x the volume of
the ligation reaction for the SPRI cleanup to maximize recovery of the tRNA.
With such a high ratio of SPRI beads the unligated tRNA and free splint adapter
is also collected as well. There was a need to optimize the SPRI bead conditions
used in the cleanup steps to maximize the amount of ligated tRNA recovered while
minimizing other extraneous RNA. I did a bulk scale ligation using IVT produced
bovine fmet tRNA purified with a P6 column. The reaction was split up evenly
for 5 SPRI cleanups. The SPRI cleanups were done at 1.8x, 2.0x, 2.25x, 2.5x and
3.0x, Figure 3.3. The SPRI cleanups have made a marginal difference in material
recovery. All washes recovered some amount of adapter boxed red and partially
ligated material in green. The 2.25x cleanup recovered the most amount of RNA,
85.8 ng, however there is a significant amount of adapter remaining. At the
2.0x and 1.8x SPRI concentrations, unligated adapter and partially ligated tRNA
populations are recovered proportionally less. It is important to note the parabolic
nature of the recovery, going above or below 2.25x SPRI decreases recovery. In the
1.8x, 2.5x, and 3.0x cleanups, the amount of material recovered was 66 ng, 68.2 ng
and 66 ng respectively. From this gel, the 2.5x and 3.0x lanes have significantly
more adapter as the bands are brighter, than the 1.8x lane. The NanoDrop results
in conjunction with the gel suggest that a more stringent SPRI wash removes a
greater proportion of extraneous adapter at the cost of recovery. The hypothesis
is that either small adapters or unligated tRNAs are causing clogs; decreasing the
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volume of the SPRI cleanup was the best option.
In lane 8, 100 ng of the synthetic fmet tRNA, 77 bases, based on E. coli fmet
sequence purchased from Dharmacon was loaded. There is a single bright band at
the 80 base marker and no other minor bands. Upon confirming the ligation of the
biological fmet tRNA in previous work, the project oriented towards sequencing
both modified and canonical versions of E. coli fmet tRNA. The current library
preparation protocol uses SPRI washes at 1.8x and 1.5x the volume of the first
and second ligation reaction respectively.
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Figure 3.3: Optimizing SPRI Cleanup
The 8% PAGE, stained with SYBR gold, shows how varying the stringency
of the SPRI wash on IVT constructed tRNA affects recovery. In these lanes,
bands believed to be splint adapters, 24 and 30 bases are boxed red, partial
ligations, 96-102 bases, green and complete ligations, 126 bases, blue. The
last lane contains the synthetic fmet tRNA purchased from Dharmacon to
confirm its purity. All samples are in NEB 2x RNA dye.
1) Crude ligation reaction, to
confirm ligation occurred.
2) SPRI cleanup, 3.0x SPRI
beads, 66.0 ng loaded into lane.
3) SPRI cleanup, 2.5x SPRI
beads, 68.2 ng loaded into lane.
4) SPRI cleanup, 2.25x SPRI
beads, 85.8 ng loaded into lane.
L) NEB low range ssRNA lad-
der.
5) SPRI cleanup, 2.0x SPRI
beads, 78.0 ng loaded into lane.
6) SPRI cleanup, 1.8x SPRI
beads, 66.0 ng loaded into lane.
7) IVT produced Bovine fmet
tRNA, expected size of 72
bases.
L) NEB low range ssRNA lad-
der
8) Synthetic E. coli fmet tRNA
manufactured by Dharmacon,
77 bases long.
24
fmet Biological and Synthetic Ligations:
Figure 3.4 shows the ligation of the biological E. coli fmet tRNA and its
canonical copy. The ligations shown are sampled from library preparations. Lanes
1-3 focus on the biological tRNA and lanes 4-6 are the synthetic tRNA. The
ligation of the M221/AS102 adapters to the biological tRNA was successful. Lane
1 shows the ligation of the biological E. coli fmet tRNA, 77 bases, to the splint.
The tRNA is visible at the 80 base marker in lane 1. There is a partial ligation
and a complete ligation, both between 80 and 150 bases. The splint ligation of
synthetic tRNA, lane 4, also occurs successfully. In lane 4 the tRNA is visible as
a faint band at 80 bases followed by the complete ligation below 150 bases. When
the gel is exposed for a longer period there is a partial ligation visible as well, see
supplements. The ligation of the ONT RMX adapters to the tRNA is not visible
in either lanes 2 or 5.
The banding patterns of the splint ligation, lane 1 and lane 4, show that
ligation is inefficient with a significant amount of unligated and partially ligated
tRNA. In order to better understand how much tRNA is being ligated, lane 7 was
loaded with 50% of a standard ligation reaction using synthetic fmet tRNA. This
is approximately 125 ng of tRNA. In this lane there is a bright adapter band,
followed by tRNA at 77 bases. Between the 80 base and 150 base marker, there
are two bands, corresponding to the partial ligation and the complete ligation.
In addition there is a band above the 150 base marker that appears to be an
unknown product, at higher exposure this product is also visible in other lanes (see
supplements, page 5). This band may be material that has not fully denatured
or dimerized. To test this, the band will be excised from the gel and run in a
second denaturing gel. If the band migrates lower this would suggest incomplete
denaturation of the sample and more loading buffer and heat is necessary. If
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it is the formation of other ligation products, the relative intensity of the band
suggests it is a minority product and size exclusion based purification such as gel
purification can be used to remove these products.
The gel shows that the splint ligation did occur for the sequencing runs of the
synthetic and biological tRNA, however it is not efficient. The RMX ligations in
lanes 2 and 5 are not visible, however tRNA was sequenced, reported in Table 3.1.
The lack of visible bands is likely caused by the amount of mass loaded into the
gel. The SPRI cleanup recovers <100 ng for any of the SPRI concentrations used,
see Figure 3.3. Assuming a best case scenario of 50% recovery, the concentration
of tRNA in ligation 2 is 5 ng/µL. These lanes contain 1 µL of the ligation reaction.
In the second ligation the concentration of nucleic acid is too low to see on PAGE
stained with SYBR gold. While these sequencing runs were able to generate some
data, Table 3.1, the flow cells also failed to sequence for a full day as the pores
would eventually get clogged. The gel shows that the splint ligation is inefficient
as a significant amount of material is partially ligated or not ligated at all. If
unligated tRNA is carried forward it may not translocate through the pore as
ligation of the RMX adapter is hindered. In addition without both ends of the
splint adapter attached there is an effect on coverage, Table 3.2. A major future
goal is improving the efficiency of splint ligation and selection for fully ligated
tRNA.
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Figure 3.4: Ligation of E. coli Synthetic and Biological fmet tRNA
Below is an 8% PAGE, stained with SYBR gold, showing the ligations of
the E. coli biological tRNA and the synthetic fmet tRNA. Lane 7 is half the
splint ligation for synthetic fmet tRNA. This figure also has companion in
the supplements with a longer exposure showing additional bands. Adapter
bands are labeled with an A. Partial ligations are labeled with a P. CL is
used to denote complete ligation. All samples are in NEB 2x RNA dye.
L) NEB low range ssRNA ladder
1) Ligation of splint adapters to E. coli
fmet biological tRNA.
2) Ligation of the RMX adapters to the
product of the first ligation, lane 2. No
bands are visible.
3) Biological E. coli fmet tRNA, ex-
pected size is 77 bases.
L) NEB low range ssRNA ladder
4) Ligation of splint adapters to E.
coli fmet synthetic tRNA. A partial
band is present when exposed for longer
amount of time.
5) Ligation of the RMX adapters to the
product of the first ligation, lane 4. No
bands are visible.
6) Synthetic E. coli fmet tRNA, size is
77 bases.
7) 50% of the splint ligation reaction
using synthetic E. coli fmet tRNA as
the substrate. The blue box indicates
the presence of an unknown product to
large to be the ligation.
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Confirming AS102_18 and M221_6 Splint Ligation:
Early alignments showed low coverage at the terminal edges of the tRNA,
specifically at the 3′ end, see Table 3.2. The hypothesis is that addition of more
RNA on either side of the tRNA would improve coverage. The logic for additional
ribonucleotides flanking that tRNA is to provide the basecaller more raw current
signal. This allows the basecaller to start calling the adapter region first before
entering the tRNA and improve basecalling accuracy and coverage. The basecaller
then has more data before and after the tRNA to more accurately determine the
ends. The simplest adjustment to make to the adapters was replacing regions ad-
jacent to the tRNA with corresponding ribonucleotide bases. These new adapters
AS102_18 and M221_6 have 18 and 6 ribonucleotide bases to flank the tRNA on
both ends. Direct RNA sequencing on the MinION works by translocating RNA
3′ to 5′. The presence of ribonucleotides prior to the 3′ CCA tail should improve
coverage at the CCA tail by providing additional information for basecalling.
After purchase of the new adapter oligos they were hybridized and tested on
the synthetic E. coli fmet tRNA to confirm ligation. Figure 3.5 shows ligation
of the tRNA to the new adapters, along with a set of controls. Lanes 1 and 2
contain the tRNA and splint adapters respectively. Lane 3 is the negative control,
no T4RNL2 enzyme, the tRNA and adapters are visible as clear bands. Ligation
products are expected to be above the 80 base marker, in the negative there are
no ligation products as expected. Lane 4 is the ligation, with the AS102_18
adapter only. In this lane there are bands corresponding to the tRNA and the
AS102_18 adapter but no evidence of partial ligation. Lane 5 is ligation with the
M221_6 adapter only and there is a faint band above the tRNA band, not present
in the negative control. This evidence suggests that partial ligation of M221_6
at the 3′ end of the tRNA is possible, but happens very inefficiently. In lane 6 all
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components of the ligation are included. In this lane there is evidence of partial
ligation most likely with M221_6 as the band migrates to the same position as
the ligation band in lane 5. The complete ligation product, 131 bases, is visible
under the 150 base marker in lane 6. There is also a smear under this band as
well. It is unknown if the smear is the complete ligation or other fragments still
migrating down. Lanes 6 shows that the new adapters are able to ligate to the
tRNA and lane 5 shows that M221_6 is able to ligate to the tRNA by itself. I
have confirmed that the modified RNA/DNA hybrid adapters are able to ligate
to the tRNA using the same T4RNL2 enzyme.
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Figure 3.5: Ligation of AS102_18 and M221_6
This 8% gel, stained with SYBR gold, shows the ligation of synthetic fmet
tRNA to the AS102_18 and M221_6 ribonucleotide heavy adapters and
controls. All samples are in NEB 2x RNA dye. The results of this gel
show that splint ligation to the tRNA is possible even with the increase in
ribonucleotide bases of each adapter. In addition M221_6 is able to ligate
to the tRNA by itself but the 5′ AS102_18 ligation by itself is unlikely.
L) NEB low range ssRNA ladder
1) Synthetic fmet tRNA, 77
bases.
2) Hybridized mixture of
M221_6, 30 bases, and
AS102_18, 24 bases in green
boxes.
3) Negative control with no
enzyme.
4) Ligation with AS102_18 por-
tion of adapter only. No product
formed.
5) Ligation with M221_6 only.
Faint band, labeled at 107 bases,
is visible. This suggests partial
ligation is possible.
6) Ligation reaction with all
components. There is evidence
of both a partial and complete
ligation.
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Summary of Sequencing Runs
Tables 3.1 and 3.2 provide information about the sequencing runs, including
the number of aligned reads and number of full length reads. Tables 3.1 and
3.2 show the effects of longer flanking ribonucleotide regions on coverage of the
tRNA at its terminal ends. The effects of switching from the original AS102/M221
adapters to AS102_18/M221_6 for each construct are discussed separately.
For the synthetic construct there were two sequencing runs, one with the
original M221/AS102 adapter mix and the second with the AS102_18/M221_6
adapter. The results of the sequencing run can be seen in the table below. The
first run with the original adapters had 40,353 reads and the second run used
AS102_18/M221_6 had 36,234 reads basecalled. While the number of reads de-
creased between the first and second run, the number of aligned reads to the
reference sequence increased. The run with the original adapters only had 5.87%
of the reads align, increasing to 14.18% with the new adapters. The number of
full length reads increased from 808 for the original adapter to 3,127. A major
goal was improving coverage at the terminal ends. With the M221_6 adapter,
the basecaller has signal to call before entering the 3′ end of the tRNA. Sequenc-
ing runs of both biological and synthetic tRNA show improvement in coverage
at terminal ends of the tRNA when using the ribonucleotide containing adapters.
The 5′ coverage increases from 64.89% to 72.21% and 3′ coverage increases from
55.94% to 86.82%. While the sample space for the synthetic construct is small, a
similar trend in coverage also occurs for the biological tRNA.
For the biological E. coli fmet tRNA, 5 sequencing runs were done of which
2 used the AS102_18/ M221_6 adapters. The 01/23/19, original adapters, and
01/30/19, new adapters, runs are the most comparable biological runs, as they
used the same SPRI purification ratios and same ONT library kits. With the
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original adapters, 2.84% of the reads aligned, with AS102_18 and M221_6 that
rose to 14.74%. The number of full length reads increased as well. The number
of full length reads increased to 79.82% from 45.12% when using SAMtools to
filter full length reads. In addition coverage at the 5′ end improved. With the
original adapters 85.23% of the reads covered the 5′ region improving to 90.39%
when using AS102_18/M221_6. The 3′ end also saw a large increase in coverage.
The jump was from 53.05% to 89.04%, similar numbers to the synthetic.
When comparing all runs in aggregate there is an increase in the number of
alignments when using the AS102_18/M221_6 adapter pair as compared to the
original adapters. The coverage also improves at the terminal ends of the tRNAs.
The 3′ coverage had a drastic improvement, with the original adapters less than
60% of the reads covered the CCA tail increasing up to 89.04% for the highest
biological tRNA run. The 5′ end of the tRNA was flanked by ribonucleotides
with the original AS102 adapter, however there is small increase in coverage with
AS102_18. It is less than 10% but this increase is noticeable and consistent across
all biological runs. The average coverage at the 5′ terminal for the 3 biological
runs with the original AS102/M221 adapters is 84.39% was boosted to 91% in the
two runs with AS102_18/M221_6. For the synthetic it was an 8% increase.
Table 3.1: Summary of fmet Biological and Synthetic Sequencing Runs
Date Sample Adapter Reads %Aligned
% Full
Length
10/17/18 biological AS102/M221 42681 3.12 38.95
11/14/18 biological AS102/M221 111238 3.43 42.99
12/03/18 synthetic AS102/M221 40353 5.87 34.14
01/09/19 synthetic AS102_18/M221_6 36234 14.18 60.86
01/23/19 biological AS102_18/M221_6 80893 14.74 79.82
01/30/19 biological AS102/M221 51895 2.84 45.12
02/04/19 biological AS102_18/M221_6 137553 20.28 80.26
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Table 3.2: Summary of Coverage for Sequencing Runs
Date Sample Adapter % 5
′ cov-
erage
% 3′
cover-
age
10/17/18 biological AS102/M221 83.46 46.92
11/14/18 biological AS102/M221 84.49 51.59
12/03/18 synthetic AS102/M221 64.89 55.94
01/09/19 synthetic AS102_18/M221_6 72.21 86.82
01/23/19 biological AS102_18/M221_6 90.39 89.04
01/30/19 biological AS102/M221 85.23 53.05
02/04/19 biological AS102_18/M221_6 91.61 88.23
The data suggests that flanking the tRNA with more ribonucleotides has an
improvement on coverage at the terminal regions around the tRNA. This can
qualitatively be seen in the IGV screen captures included in the supplements,
pages 2-4. Coverage of the 3′ CCA tail is relatively lower in the alignments
without the modified adapters. In addition the percentage of alignments increases
and among those alignments the number of full length reads also increases. The
percentage of reads that cover either the 5′ or 3′ end of the tRNA stays relatively
consistent throughout the biological samples regardless of library preparation or
kit used, only changing as a function of the adapter used. It is unknown if this
trend will be true for synthetic reads. The improvement in coverage was similar
to the biological runs however more sequencing runs with the synthetic will need
to be carried out.
ONT’s basecaller uses a recurrent neural network paradigm, which relies on a
notion of past and future data points existing. This allows the basecaller to con-
sider how previous bases will affect the next base. The addition of ribonucleotide
regions flanking the tRNA on either side provides more raw current signal and
thus more data points for the basecaller to more accurately determine the termi-
nal bases on the tRNA. Using the original M221 adapter there were no ribonu-
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cleotide bases preceding the tRNA to provide information for basecalling. After
redesigning the splint adapters to have more RNA sequence, there is an increase
in coverage on the 3′ of the tRNA. In addition while the original AS102 adapter
did have ribonucleotide bases there was still an improvement when switching to
the AS102_18 adapter, this suggests that more ribonucleotide bases flanking the
tRNA could further improve basecalling at terminal ends of the tRNA, up to the
limits of nanopore error.
Table 3.3: Summary of Mass Spectrometry
Modification Mass(amu)
[M+H]+
(m/z)
Breakdown
product
(m/z)
Visible
4-thiouridine (4) 260.0467 261.00545 129 unknown
2′-O-methylcytidine (B) 257.1912 258.1082 112 Y
7-methylguanosine (7/m7g) 299.123 298.1151 166 Y
5-methyluridine (T) 258.0852 259.093 127 Y
pseudouridine (P) 244.0695 245.0773 209/179155
Break-
down
products
visible
Difference in Alignment Profiles of Canonical and Biological tRNA:
The motivation for running the biological and synthetic version of the same
tRNA was to determine the sensitivity of the MinION to modifications. If modi-
fications perturb the measured current it will have an effect on basecalling. The
basecaller, Guppy, is designed report canonical bases, but the nanopore itself can
process analytes that have been modified. This disparity between what occurs
in biology and the limitations of basecalling software may cause modified nucleo-
sides to present themselves as mismatches and indels when aligned to the reference
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Figure 3.6: E. coli fmet tRNA is shown against the synthetic equivalent, there
are regions of mismatches shown in the coverage plot, colored bars, that are differ-
ent between the biological, top, and synthetic, bottom. IGV was used to visualize
a downsampled set of alignments.
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sequence. This difference in alignment space should be consistent and errors at-
tributed to modifications should be higher than what is expected of the MinION.
The canonical synthetic provides a baseline to differentiate expected nanopore
basecalling error from error due to modifications. Detection of modifications via
nanopore is not novel. Smith et al. showed that 7-methylguanosine perturbs
current such that a systematic difference can be seen in MinION current traces
[19]. In addition to sequencing both the synthetic and biological fmet tRNA, mass
spectrometry of the biological sample was carried out by a member of the UCSC
Nanopore Group. The results are summarized in Table 3.3. The values for mass
charge ratios were taken from Pomerantz et al. and Modomics [14, 2]. Of the six
modifications reported to be present on E. coli fmet tRNA, four were confirmed
to be present.
Figure 3.6 is the alignments of a biological fmet tRNA (top) sequencing run
against a synthetic tRNA run (bottom). The specific samples are 01/23/19, bi-
ological, and 01/09/19, synthetic. These two samples were prepared using the
same library preparation protocol. There is a significant difference in alignment
profiles, looking at the coverage plots in the IGV browser; there are more areas
(colored bars) in which mismatches occur for the biological. This is believed to be
caused by modifications, as many regions of mismatches unique to the biological
are proximal to the positions of modifications.
The first modification 4-thiouridine, 4, occurs at base 26 in the reference se-
quence. In both the synthetic and biological this base and proximal positions
do not show any form of indel or systematic mismatch. Most of the reads that
aligned at this position did not have deletions providing high coverage, and there
is very little indication of systematic mismatches. The mass spectrometry results
for this modification was inconclusive as there was no evidence of a product ion
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peak in either the biological or standard. This modification will require future
exploration, but it is unlikely to be present in the biological sample.
The next modification is dihydrouridine, D, which occurs at position 39. In
the biological sample there is a region from positions 33-38 having mismatches.
At position 39 the reference base, uridine is called more than 80% of the time,
when looking at all biological runs it is only bases 35 and 38 that suffer from
mismatches not the whole intervening region, regardless of adapter. One thing
to note is that nanopore reads multiple bases at a time, rather than a single
nucleotide so modified nucleosides can affect basecalling of proximal bases not
just the base where the modification occurs. If the modification is truly present
in significant levels it may be that the modification affects bases at its 5′ proximal
position rather than the base itself. In the synthetic runs the mismatches do not
occur as often at either positions 35 or 38. This suggests that this state is intrinsic
to the biological tRNA itself.
At position 51 is 2′-O-methylcytidine, B. This modification was verified to be
present with mass spectrometry data, and has strong breakdown product peak.
The evidence suggests that it exists in the biological sample. Here positions 47, 49
and 52, have mismatches and it is consistent among all biological samples regard-
less of adapters. Neither of the two synthetic runs suffer from mismatches at the
same frequency as the biological in this area. In the biological sample the refer-
ence base is called more than 80% of the time at the position of the modification.
Much like dihydrouridine it may be possible that effects of the modification are
proximal to the modification rather than the site of the modification itself. Both
the mass spectra and the alignments point towards the modification occurring in
the biological.
7-methylguanosine, 7, occurs at position 65. This modification has a very
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prominent peak on the mass spectra digest of the biological tRNA. In the align-
ment profile it appears that the modification exists and causes a significant effect
on the alignments as positions 62-66 suffer from a wide variety of mismatches. This
pattern is consistent across all of the biological samples and does not occur at all in
the synthetic. In the synthetic runs, reads that called a base at position 65 called
the reference more than 80% of the time. The alignment profile having a large
perturbed region in the area of the modification combined with the mass spectrom-
etry results are indicative of the biological tRNA having the 7-methylguanosine
modification. Clinically this is very useful, as one of the enzymes responsible for
7-methylguanosine modification in humans, WDR4 when mutated, results in the
7-methylguanosine modification to be lost from tRNAs. This mutation is also
known to cause microcephalic primordial dwarfism [21]. This is an opportunity
in which tRNA sequencing may provide clinical information, bypassing the need
for DNA sequencing and RNA-expression analysis. 7-methylguanosine causes a
significant perturbation in the signal, as the whole region proximal to the site of
modification significantly differs from the reference sequence.
The last two modifications occur consecutively, at position 73 is 5-methyluridine,
T, and at 74 is pseudouridine, P. There is a small peak in mass spectrometry for
the presence of 5-methyluridine along with presence of its product ion. For pseu-
douridine the mass spectrometry data shows peaks corresponding to breakdown
products that are not expected for uridine but for pseudouridine. Mass spec-
trometry alone suggests the presence of both these modifications, however the
alignments are more difficult to decipher. At position 73 there is a drop in cov-
erage, rather than mismatches. There is a clear mismatch pattern that occurs at
position 74 where pseudouridine is located. For the biological reads that spanned
position 73, many of the reads have a deletion at that position. For the biological
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sequencing runs, the frequency of reads with a deletion where 5-methyluridine oc-
curs ranges from 16%-25% for each run. In the synthetic the number of reads with
a deletion at that position stays below 10%. Pseudouridine displays an interesting
state as it most often interpreted as a cytosine rather than a uracil ranging from
44% to 51% at its highest in the biological runs. For the synthetic runs, position
74 is properly interpreted as a uracil more than 90% of the time. In addition the
coverage is very high at this position. For 5-methyluridine the mass spectra plot
shows a low abundance of the product ion. If 5-methyluridine is only present in
low abundance in this biological sample it may not have a significant effect in
alignment space.
There are common errors throughout the synthetic and biological alignments
that stem from homopolymeric repeats and at points close to positions of ligation.
At the start of the tRNA, position 19, there is a drop in coverage and a mismatch
occurs in both the biological and synthetic. The 5′ start of the E. coli fmet
tRNA does not base pair with the stem as it does in other tRNA. This may
create a bubble during the ligation of the 5′ adapter. Another consistent error
is at positions 22-24 where there is a stretch of guanosine with an intervening
cytosine that likely confuses the basecaller as the tRNA enters the pore 3′ first.
There is dip in coverage at position 54. There are a large number of deletions at
this position across all runs. This region falls within the region of the anticodon
loop. This area has very small homopolymeric runs, that may affect basecalling
accuracy. The last place there is common error is at positions 88 and 90. This
is at the 3′ end of the tRNA before the CCA tail. In this case there are small
homopolymer repeats, specifically there is a repeat of Cs that is interspersed with
a consecutive set of As. The mismatch at these positions are consistent across
all runs, the mismatched base is usually called as uracil instead of the reference
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cytosine. In one of the runs for the biological sample using the M221_6 adapter,
position 90 is not colored by IGV in the coverage plot. When this run is inspected
by hand it does show a similar error profile at this position with 25% of the reads
that call a base at this position calling uracil as well. In the synthetic there are
positions that show mismatches that are not present in the biological, this may
be the affects of modifications on basecalling affecting the signal such a way that
certain regions are more accurately called.
Comparing the alignments of both the synthetic and biological run suggests
that the presence of modifications affects nanopore basecalling. Of the six modifi-
cations that are known to occur on this tRNA, mass spectrometry is inconclusive
about 4-thiouridine and alignments suggest that modification is not there or it
does not perturb current enough to affect basecalling. Dihydrouridine could not
be confirmed with mass spectrometry however there is a difference in the align-
ment profiles of the synthetic and biological at bases proximal to the location
of this modification. This difference only occurs in biological samples and not
the synthetic suggesting that modification may have an effect on proximal bases.
All other modifications on the tRNA were confirmed with mass spectrometry,
with 7-methylguanosine having the strongest effect on basecalling accuracy. 2′-O-
methylcytidine creates errors at regions proximal to modification itself, rather than
the position of the modification itself. The last two modifications pseudouridine
and 5-methyluridine occur consecutively making it difficult to determine whether
it is the effect of both modifications that causes the profile seen. At position 73
there are more deletions in the biological than the synthetic. Without additional
molecules that contain 5-methyluridine independent of pseudouridine it is diffi-
cult to conclude if 5-methyluridine has an affect on basecalling. In addition the
mass spectra plot suggests that 5-methyluridine is not in high abundance in the
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sample. 5-methyluridine modifications are controlled by the TRMT2A gene in
humans which may have a role in cancer [22]. The results of TRMT2A expression
studies are mixed but the gene may be overexpressed in certain breast cancers
making it a valuable marker for sequencing based diagnosis [4]. If it is possible to
link enzymes that modify tRNAs with disease phenotypes it may be possible to
relate tRNA modification rates with diseases as well. The alignments show the
potential of nanopore sequencing to recognize modifications. The work so far fo-
cuses on the effects of modifications on basecalling. Working at the signal level it
may be these modifications could be detected and called natively, with progressive
updates to the basecaller itself. Modification detection on the nanopore is still
in its infancy, and the long range of effects of modifications on neighboring bases
will be a focus of future research.
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Chapter 4
Conclusion and Future Work
The results shown builds on the previous work of my colleagues. I have shown
it is possible to translocate tRNAs through nanopores on the ONTMinION device.
In addition this work provides a paradigm to detect modifications on tRNA. By
sequencing biological E. coli initiator tRNA and a synthetic canonical construct, I
have shown a difference in the alignment profiles. Many of the regions that differed
between the biological tRNA and synthetic are likely due to modifications, con-
firmed with mass spectrometry, the most striking of which is 7-methylguanosine.
Future Work:
While I have made progress on sequencing tRNAs there are improvements to
be made. The biggest issue is fixing subpar throughput. The MinION platform
is designed to generate hundreds of thousands of reads. The best sequencing run
had less than 200,000 reads. Throughout the runs, nanopores ended up clogged.
The culprit is likely unligated or partially ligated tRNA entering the pores and
getting stuck. The system attempts to eject the material but fails to do so,
ultimately causing the pore to go out of commission. tRNAs are heavily modified
and many of the modifications reported for E. coli fmet tRNA were verified,
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however quantification of the modifications in the sample still has yet to be done.
The current method is focused on determining the presence of modifications, but
not how often they are present.
Future work will focus on the following: improving throughput, modification
detection, signal-level analysis, and working with mixed sets of tRNAs. The
biggest issue is improving throughput. If low throughput is caused by inefficient
ligation, this could be solved by adjusting the library preparation steps. This
includes more stringent SPRI washes to remove smaller material, adjusting the
stoichiometry of the ligation, or looking at other methods such as gel purifica-
tion of fully ligated material. In addition methods such as biotinylated adapters
are being looked at as this presents an opportunity to selectively target tRNA in
an impure sample. If a combination of these methods improves the ligation effi-
ciency of the tRNA the next step is to sequence a mixed sample of tRNA. Many
strains of E. coli are well documented in addition their tRNAs can be ordered
commercially (Sigma Aldrich: 10109541001). The current method developed pro-
vides a framework in which tRNAs could potentially be sequenced in bulk. The
alignments can the be combined with databases such as Modomics that provide
information about the positions of modifications on tRNAs, to filter for modifi-
cations that may potentially perturb the signal. This could be used to develop
a guided training set for newer basecallers in an efficient manner as tRNAs are
modification dense. A more near term goal is a simple binary classification of
modification presence. In regards to the E. coli fmet tRNA there is no proof of
the 4-thiouridine modification, nor is it possible conclude the individual effects of
pseudouridine and 5-methyluridine on basecalling accuracy. A future test would
be to sequence this modifications independently. This will provide data regarding
the effects of sequence context and the effects of consecutive modifications on the
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current signal.
The rise of next generation sequencing has resulted in an abundance of data
for diagnostic purposes. Direct RNA-sequencing is one of the newest methods,
however the MinION has primarily been focused on long poly-A transcripts leaving
small RNA out of the picture. tRNAs are essential to life and small mutations
could have a large impact on overall health and quality of life. Sequencing tRNAs
and the detection of their modifications could have a huge impact not just on
sequencing technology applications but also healthcare. The MinION is a simple
sequencing platform that requires very little desk space and only a laptop for
sequencing. It does not take a special analyst to run the hardware or software
components. A test case with an E. coli tRNA has shown that the MinION
can directly sequence tRNAs and potentially be used to detect modifications.
Continuing to sequence additional tRNAs may provide new insights into one of
the most fundamental elements of biology.
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